Private Placement

Revive Therapeutics (RVVTF) is extending its private placement to raise up to $650,000 by issuing units at $0.021 each. Each unit includes a share and a warrant exercisable at $0.05 for 36 months. Having already raised $60,900 in the first tranche, the remaining $589,000 will be used for working capital and settling trade payables. The securities are subject to a four-month and one-day hold period. While providing needed capital, the offering involves significant dilution potential for shareholders.

Kronos Worldwide (KRO) is issuing €75M in additional 9.50% Senior Secured Notes due 2029 through its subsidiary, Kronos International, Inc. This increases the outstanding amount of these notes to €426.174M. Proceeds will primarily address maturing 3.75% Senior Secured Notes due September 2025, or repay amounts drawn from the Wells Fargo credit facility for the same purpose. The offering’s completion is subject to market conditions. The notes are guaranteed and secured by company assets.

Silver One Resources (SLVRF) increased its private placement to $6,016,600 due to oversubscription, offering 21,487,857 units at $0.28 each, comprising one common share and a half-warrant. Warrants allow purchase of a share at $0.40 within three years. Proceeds will fund exploration/drilling and working capital. The offering is subject to TSX Venture Exchange approval and a four-month resale restriction. Silver One focuses on silver project development, including the Candelaria Mine in Nevada.

Defence Therapeutics (DTCFF) announced a non-brokered private placement to raise up to $1.2 million by offering debenture units priced at $1,000 each. Each unit includes an 8% convertible debenture (convertible at $0.60 per share) maturing in two years and 1,666 common share purchase warrants (exercisable at $0.75 per share for two years). Interest will be paid annually in cash or shares at the company’s discretion. Securities are subject to a four-month hold. The offering aims to fund the company’s antibody-drug conjugate (ADC) programs.

Discovery Energy Metals (DEMCF) closed a $1 million non-brokered private placement, issuing 10 million units at $0.10 each, comprising one common share and a transferable warrant. Warrants are exercisable at $0.15 per share for 24 months. Proceeds will fund working capital and property exploration. Issued securities are subject to a four-month statutory hold. The placement creates immediate shareholder dilution, with potential for further dilution upon warrant exercise.

Cambricon, a Chinese AI chip company, has received approval from the Shanghai Stock Exchange for a RMB 4 billion private placement. The funds will be used for AI chip and software platform development, particularly for large-scale AI models, and to supplement working capital. Cambricon’s Q1 2025 revenue surged by 4230.22% year-on-year, with net profit also significantly increasing. The company focuses on cloud, edge products, and IP licensing, aiming to build a comprehensive AI ecosystem.

bioAffinity Technologies (BIAF, BIAFW) secured financing through securities purchase agreements with investors, involving the sale of Series B Convertible Preferred Stock and warrants to purchase common stock in a private placement. They also reached a warrant exercise agreement, generating $253,000. These transactions aim to raise approximately $1.2 million for working capital and general corporate purposes, supporting the development and commercialization of their CyPath® Lung test, a non-invasive early lung cancer detection method with reported 92% sensitivity. WallachBeth Capital LLC acted as placement agent.

Ligand Pharmaceuticals (LGND) priced $400M convertible senior notes due 2030 in a private placement. The notes have a 0.75% interest rate and an initial conversion price of $194.79 per share, a 32.5% premium. Ligand expects $386.9M net proceeds, using $39.9M for hedge transactions, $15M to repurchase shares, and the rest for corporate purposes. The notes can be converted under certain conditions, and Ligand may redeem them after October 2028 if its stock price reaches 130% of the conversion price.

Revive Therapeutics (RVVTF) closed the first tranche of its private placement, raising $60,900 by issuing 2.9 million units at $0.021 each. It also settled $67,400 in debt by issuing 3.2 million units at the same price. Each unit includes a share and a warrant exercisable at $0.05 for 36 months. The proceeds will fund working capital and payables. Securities are subject to a hold period expiring December 9, 2025. The offering included 100,000 compensation options to an investment dealer.

SenesTech, Inc. (SNES), a biotech company specializing in fertility control for pest management, announced the closing of a warrant exercise generating $6.3 million. The company issued new short-term warrants priced at $0.125, potentially yielding an additional $11.5 million if fully exercised. SenesTech intends to use the net proceeds for working capital and general corporate initiatives. Their flagship product, ContraPest®, is a registered contraceptive for rats, aiming for humane and ecologically-sound pest control.